Real-life clinical use of natalizumab and fingolimod in Austria.

about

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis

P2860

Q58564004-20674053-B75A-45D5-99F4-A99516D5B624

P2860

Real-life clinical use of natalizumab and fingolimod in Austria.

Item

http://www.wikidata.org/entity/Q47437600

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Real-life clinical use of natalizumab and fingolimod in Austria.

@en

Real-life clinical use of natalizumab and fingolimod in Austria.

@nl

type

Item

label

Real-life clinical use of natalizumab and fingolimod in Austria.

@en

Real-life clinical use of natalizumab and fingolimod in Austria.

@nl

prefLabel

Real-life clinical use of natalizumab and fingolimod in Austria.

@en

Real-life clinical use of natalizumab and fingolimod in Austria.

@nl

P1476

Real-life clinical use of natalizumab and fingolimod in Austria

@en

P2093

C Enzinger

http://www.w3.org/2001/XMLSchema#string

E Kvas

http://www.w3.org/2001/XMLSchema#string

F Leutmezer

http://www.w3.org/2001/XMLSchema#string

S Kalcher

http://www.w3.org/2001/XMLSchema#string

T Berger

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.

Fingolimod after natalizumab and the risk of short-term relapse.

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.

P304

181-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ANE.12864

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

J Kraus

M Guger

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29159801

http://www.w3.org/2001/XMLSchema#string

Real-life clinical use of natalizumab and fingolimod in Austria.

about

P2860

P2860

Real-life clinical use of natalizumab and fingolimod in Austria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698